系统性硬化症患者报告结局测量工具的研制与验证:EULAR系统性硬化症疾病影响问卷(ScleroID)
这项EULAR背书的欧洲11个系统性硬化症中心项目,与患者专家共同从17个健康维度中选出前10个构建ScleroID问卷,并在472例患者的观察性队列中按OMERACT标准进行横断面与纵向验证。ScleroID总分与SSc-HAQ、患者总体评估等强相关,内部一致性Cronbach's alpha 0.87,重测信度组内相关系数0.84,标准化反应均数0.57,对变化的敏感性优于所有对照工具。
要点
- ScleroID由患者优先选出的10个健康维度构成,其中雷诺现象、手功能受损、疼痛和疲劳报告影响最高。
- 验证队列472例,重测信度亚组109例,随访亚组113例,85%为女性,38%为弥漫型SSc。
- ScleroID总分与SSc-HAQ相关系数0.73,与患者总体评估视觉模拟量表0.77,与HAQ残疾指数0.62,与SF-36躯体评分-0.62,各p<0.001。
核心结论
- 研究研制并验证了EULAR ScleroID,这是一种新型、简短、疾病特异性、源自患者的疾病影响患者报告结局测量工具,适用于系统性硬化症的研究与临床使用。
研究设计与样本
- 这是一项EULAR背书的项目,涉及11个欧洲系统性硬化症中心,健康维度由患者选择并排序。
- ScleroID问卷随后在观察性队列研究中按OMERACT标准进行权重设定与验证,包括横断面和纵向评估。
- 验证队列纳入472例患者完成基线访视,其中109例完成重测信度访视,113例完成随访访视;85%为女性,38%为弥漫型系统性硬化症,平均年龄58岁,平均病程9年。
- 对照工具包括系统性硬化症健康评估问卷(SSc-HAQ)、欧洲五维健康量表(EQ-5D)和36项简短健康调查(SF-36)。
主要发现
- 初始选出17个健康维度并排序,最终选取前10个健康维度构成ScleroID问卷。
- 患者报告的疾病影响最高的维度为雷诺现象、手功能受损、疼痛和疲劳。
- ScleroID总分与对照工具呈强Pearson相关:与SSc-HAQ相关系数0.73,与患者总体评估视觉模拟量表0.77,与HAQ残疾指数0.62,与SF-36躯体评分-0.62,各p<0.001。
- 内部一致性较强,Cronbach's alpha为0.87,与SSc-HAQ的0.88相似,高于EQ-5D的0.77。
- ScleroID信度优良且对变化敏感性良好,优于所有对照工具:组内相关系数0.84,标准化反应均数0.57。
关键数值与推荐
- ScleroID问卷包含患者优先选出的前10个健康维度。
- ScleroID总分与SSc-HAQ相关系数0.73,与患者总体评估视觉模拟量表0.77,与HAQ残疾指数0.62,与SF-36躯体评分-0.62,各p<0.001。
- Cronbach's alpha:ScleroID 0.87,SSc-HAQ 0.88,EQ-5D 0.77。
- 组内相关系数0.84,标准化反应均数0.57。
临床怎么用
- 作者认为ScleroID适用于系统性硬化症的研究与临床使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patient-reported outcome measures (PROMs) are important for clinical practice and research. Given the high unmet need, our aim was to develop a comprehensive PROM for systemic sclerosis (SSc), jointly with patient experts. METHODS: This European Alliance of Associations for Rheumatology (EULAR)-endorsed project involved 11 European SSc centres. Relevant health dimensions were chosen and prioritised by patients. The resulting Systemic Sclerosis Impact of Disease (ScleroID) questionnaire was subsequently weighted and validated by Outcome Measures in Rheumatology criteria in an observational cohort study, cross-sectionally and longitudinally. As comparators, SSc-Health Assessment Questionnaire (HAQ), EuroQol Five Dimensional (EQ-5D), Short Form-36 (SF-36) were included. RESULTS: Initially, 17 health dimensions were selected and prioritised. The top 10 health dimensions were selected for the ScleroID questionnaire. Importantly, Raynaud's phenomenon, impaired hand function, pain and fatigue had the highest patient-reported disease impact. The validation cohort study included 472 patients with a baseline visit, from which 109 had a test-retest reliability visit and 113 had a follow-up visit (85% female, 38% diffuse SSc, mean age 58 years, mean disease duration 9 years). The total ScleroID score showed strong Pearson correlation coefficients with comparators (SSc-HAQ, 0.73; Patient's global assessment, Visual Analogue Scale 0.77; HAQ-Disability Index, 0.62; SF-36 physical score, -0.62; each p<0.001). The internal consistency was strong: Cronbach's alpha was 0.87, similar to SSc-HAQ (0.88) and higher than EQ-5D (0.77). The ScleroID had excellent reliability and good sensitivity to change, superior to all comparators (intraclass correlation coefficient 0.84; standardised response mean 0.57). CONCLUSIONS: We have developed and validated the EULAR ScleroID, which is a novel, brief, disease-specific, patient-derived, disease impact PROM, suitable for research and clinical use in SSc.
引用
- Becker MO, Dobrota R, Garaiman A, et al. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire. Ann Rheum Dis. 2021. PMID: 34824049. doi:10.1136/annrheumdis-2021-220702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。